Celltrion Healthcare Co Ltd
KOSDAQ:091990
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
69 900
80 400
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Celltrion Healthcare Co Ltd
Celltrion Healthcare Co Ltd
Operating Income
Celltrion Healthcare Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
Operating Income
₩194.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
C
|
Chorokbaem Healthcare Co Ltd
KRX:118000
|
Operating Income
-₩8.9B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
W
|
WSI Co Ltd
KOSDAQ:299170
|
Operating Income
₩3.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
W
|
Wonik Co Ltd
KOSDAQ:032940
|
Operating Income
₩12B
|
CAGR 3-Years
24%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
H
|
HLB Life Science Co Ltd
KOSDAQ:067630
|
Operating Income
-₩27B
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-30%
|
|
|
B
|
BlueMTec Co Ltd
KOSDAQ:439580
|
Operating Income
₩1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Celltrion Healthcare Co Ltd
Glance View
Celltrion Healthcare Co., Ltd. is a pioneering biopharmaceutical company based in South Korea, with a remarkable focus on developing and manufacturing innovative therapies that harness the power of biotechnology. Established in 2002, Celltrion has rapidly emerged as a leader in the biopharmaceutical industry, particularly known for its biosimilars and monoclonal antibody products. The company's mission is rooted in making high-quality medications more accessible and affordable on a global scale, targeting serious diseases such as cancer, autoimmune disorders, and infectious diseases. With a robust pipeline of biosimilar products aimed at offering effective alternatives to expensive biologics, Celltrion is strategically positioned to capitalize on the growing demand for cost-effective pharmaceutical solutions, especially as patent expirations of original biologics pave the way for increased competition in the market. What sets Celltrion apart is its commitment to research and development, supported by its state-of-the-art manufacturing facilities that comply with international quality standards. Its flagship products, including trastuzumab biosimilars, have already garnered approval and are being successfully marketed in multiple regions, including Europe and Asia. By leveraging cutting-edge biomanufacturing techniques and its extensive expertise, Celltrion not only reduces reliance on traditional pharmaceuticals but also addresses pressing healthcare needs globally. For investors, Celltrion presents a compelling opportunity as it continues to expand its global footprint, with increasing partnerships and collaborations aiming to unlock new markets and enhance shareholder value. As the biopharmaceutical landscape evolves, Celltrion’s innovative approach and steadfast growth trajectory position it as a formidable player, making it a company worth watching for anyone interested in the future of healthcare.
See Also
What is Celltrion Healthcare Co Ltd's Operating Income?
Operating Income
194.8B
KRW
Based on the financial report for Jun 30, 2023, Celltrion Healthcare Co Ltd's Operating Income amounts to 194.8B KRW.
What is Celltrion Healthcare Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
18%
Over the last year, the Operating Income growth was 2%. The average annual Operating Income growth rates for Celltrion Healthcare Co Ltd have been -2% over the past three years , 18% over the past five years .
You don't have any saved screeners yet
